Par Drugs and Chemicals Limited — Important, 12-02-2025: Adoption of new line(s) of business

An Extra Ordinary General Meeting (EGM) was held to address key resolutions, including the approval for a slump sale of existing assets for ₹95 Crore, which contributed 99.44% to revenue last year. The company plans to diversify into real estate, capital markets, and clean energy, with estimated investments of ₹27 Crore in each of the former two and ₹41 Crore in capital markets. This strategic shift aims to capitalize on high-growth opportunities, enhancing the company's long-term prospects. Investor sentiment may see a positive outlook as the company embraces sector diversification for better growth potential.